Adoption of the HALO® Platform at Caris Life Sciences' High Volume Digital Pathology Laboratory

Date: 17 October 2021

Time: 11:30 – 12:30 PST

Location: Workshop, Las Vegas, NV

In this one-hour pre-conference workshop, Indica Labs is pleased to host Dr. Matthew Oberley, Executive Medical Director at Caris Life Sciences, who will present a case study on deploying HALO AP® case management software in their high-volume, fully digital, anatomic pathology lab. Dr. Oberley will discuss the challenges and selection criteria that led to the adoption of HALO AP, describe the integration into their laboratory workflows, and, finally, touch on the rollout progress and future plans to utilize HALO and HALO AI.

Summary

As an introduction to the workshop, Kate Lillard, Chief Scientific Officer at Indica Labs, will present a short overview of HALO AP, its built-in AI and image analysis tools, and open pathology features that simplify third party integration and data sharing. To close the workshop, Dr. Anne Hellebust, Director of Product – Life Sciences, will present an overview of user-driven AI algorithm development for research projects or translation to clinical workflows. New HALO® and HALO AI features in 3.4 will be highlighted in this workflow

Presenters

Dr. Matthew Oberley, MD, PhD

Executive Medical Director Caris Life Sciences Education M.D. University of Wisconsin – Madison School of Medicine and Public Health Ph.D. University of Wisconsin – Madison School of Medicine and Public Health Board Certification Anatomic and Clinical Pathology Hematopathology

Dr. Oberley joined Caris Life Sciences® in 2019 where he helped manage the Precision Oncology Alliance. Prior to Caris, Dr. Oberley was on the faculty at the University of Southern California and Director of Hematopathology at Children’s Hospital Los Angeles (CHLA). He currently provides executive leadership for the growing Pathology and Molecular Genetics group at Caris Life Sciences® which includes 23 board-certified pathologists and 6 board-certified molecular geneticists. He has led the Caris Digital Pathology enterprise development and is responsible for overall quality at the clinical and R&D labs in Phoenix and Dallas. Dr. Oberley has authored over 50 peer-reviewed journal articles and book chapters in the areas of molecular biology, diagnostics, and hematologic malignancies.

Anne Hellebust, PhD

Director of Product, Life Sciences Indica Labs

Anne Hellebust earned a BS in Chemical Engineering from the University of New Mexico in 2009 and a PhD in Bioengineering from Rice University in 2015. Her thesis work evaluated the use of topically applied fluorescent contrast agent cocktails to improve early cancer detection using in vivo preclinical models. During her time in the research lab, she developed a skill set focused around confocal microscopy and image analysis. In 2016, Anne joined Indica Labs as an application scientist, providing sales and technical support to customers world-wide. In 2017, Anne became the Product Manager, Life Sciences, and advanced to Director of Product - Life Sciences in 2020.

Kate Lillard, PhD

Chief Scientific Officer Indica Labs

Kate Lillard received her Ph.D. in Molecular Genetics and Biochemistry from the University of Cincinnati Medical Center, followed by a Howard Hughes postdoctoral fellowship at the University of Texas Southwestern Medical Center. While conducting research in the area of stem cell biology and oncology as a graduate and postdoctoral fellow, Dr. Lillard developed a keen interest in IHC which led to her joining Aperio in 2007 where she supported and then managed image analysis products for digital pathology. After acquisition of Aperio by Leica in late 2012, Dr. Lillard joined Indica Labs as Chief Scientific Officer where she supports, promotes, and helps guide the development of digital pathology image analysis solutions for the life sciences.

Workshops